Ruqaya Mustafa Ali Genetic Engineering and Biotechnology.

Slides:



Advertisements
Similar presentations
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Advertisements

Diagnosis of Smear negative pulmonary TB in high HIV settings: RESEARCH PRIORITIES Haileyesus Getahun, Stop TB, WHO. Expert consultation on TB/HIV research.
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Molecular testing for detection of Mycobacterium tuberculosis San Francisco Department of Public Health Laboratory.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.
` COMPARATIVE ACCURACY OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST AND SPUTUM MICROSCOPY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN HIV POSITIVE.
New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
THE YIELD OF GENEXPERT IN PULMONARY TUBERCULOSIS&RIFAMPICIN RESISTANCE
Country Update: Tuberculosis in Thailand
1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.
Mortality Among a Tuberculosis Outbreak Los Angeles County, 2007–2013 Brian Baker, MD Amit Chitnis, MD MPH Leslie Henry, BSN RN PHN 48th CTCA Educational.
Nucleic Acid Amplification Test for Tuberculosis
World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
What Gold Standard for Rifampicin Testing?: the future of molecular testing TAG Meeting, Manila, 9-12 December 2014 Richard Lumb Mycobacterium Reference.
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
Microbiological diagnosis of TB José Domínguez 1 and Sabine Rüsch-Gerdes 2 1 Servei de Microbiologia. Fundació Institut en Ciències de la Salut Germans.
Molecular Diagnosis of Infectious Diseases. Why use a molecular test to diagnose an infectious disease? Need an accurate and timely diagnosis Important.
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
APPLICATIONS OF MOLECULAR BIOLOGY TECHNIQUES TO MEDICAL MICROBIOLOGY.
Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
Comparison of Molecular and Conventional Methods for Detection of Multidrug-Resistant Tuberculosis in the United States, 2009 to 2011 Mitchell A. Yakrus,
British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Diagnosis of TB: what is new from the laboratory
CLINICAL DIAGNOSTIC TB LABORATORY Alexander Sloutsky, Director University of Massachusetts Supranational Reference TB Laboratory Boston, MA.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
WISCONSIN STATE LABORATORY OF HYGIENE 1 State Lab Perspective Julie Tans-Kersten, MS, BS-MT (ASCP) Tuberculosis Laboratory Program Coordinator Wisconsin.
Tuberculosis: A disease caused by tiny germs that enter in lungs when someone breath them in. Mycobacterium tuberculosis is a rod shaped, non motile,
The Global Problem of Extensively Drug Resistant TB Peter M. Small, MD Institute for Systems Biology Bill and Melinda Gates Foundation February 17, 2008.
PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.
Molecular Techniques in Microbiology These include 9 techniques (1) Standard polymerase chain reaction Kary Mullis invented the PCR in 1983 (USA)Kary.
Revision of new diagnostics for TB
TB Methodologies Dr. John G. Magee Regional Reference Centre for Mycobacteriology Health Protection Agency Regional Laboratory, Newcastle upon Tyne.
Molecular diagnosis of drug resistant tuberculosis by a DNA array
Current Health Concerns: Tuberculosis Saharwash Jamali Hamna Jaffar.
Laboratory Diagnosis of Tuberculosis By Dr. Faten Aly Shoukry, Ph D Consultant & Head of Microbiology Department, Abbassia Chest Hospital.
Mycobacteria İ. Çağatay Acuner M.D., Clinical Microbiologist, Associate Professor Department of Microbiology Faculty of Medicine, Yeditepe University,
Diagnosis of pulmonary tuberculosis
Bacteriophage based test for the rapid detection & Antibiotic sensitivity test of TB Viro102: Bacteriophages & Phage Therapy 3 Credit hours NUST Centre.
Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.
Distribution of MTB among newly diagnosed HIV patients at Malindi District Hospital during July 2012 to June Sheldon kalu 1 1 Malindi District Hospital.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
Evaluation of Tuberculosis Drug Resistance among Nigerian HIV+ Patients in the Harvard PEPFAR/APIN Plus Program Using the Genotype MTBDRplus Test Lana.
REMoxTB – a microbiological challenge Dr Anna Bateson Dr. Tim McHugh, Robert Hunt, Emma Cunningham (Emily Bongard, Holly Ciesielczuk)
INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS Identification of Mycobacterium tuberculosis complex in clinical specimens of HIV-infected patients at Instituto.
TB – LABORATORY INVESTIGATIONS by Dr. Zubaidah Abdul Wahab Datin Dr. Ganeswrie Raj 1.
Article review Rapid Molecular Detection of Tuberculosis and Rifampin Resistance [MTB-RIF test] Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann,
Tuberculosis in children
Control of tuberculosis in Serbia:
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates  Muthuraj Muthaiah,
World Tuberculosis Day 2014
World Tuberculosis Day 2014
Nucleic Acid Amplification Test for Tuberculosis
Laboratory ‘Network’ Update New York State Department of Health
World Tuberculosis Day 2015
Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm  S.O. Simons, T. van der Laan,
بسم الله الرحمن الرحيم.
World Tuberculosis Day 2014
Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.
World Tuberculosis Day 2014
Timeline of development of key elements of the Cambodian MDR-TB treatment programme. *GLC1 application for patients enrolled in the CAMbodian Early vs.
Deciphering TB Lab Reports
DIAGNOSIS OF TUBERCULOSIS
Treatment of Drug Resistant TB - Questions
Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.
Presentation transcript:

Ruqaya Mustafa Ali Genetic Engineering and Biotechnology

Introduction  Tuberculosis (TB) remains a major global health problem. It causes ill-health among millions of people each year and ranks as the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV).  Tuberculosis is a major public health problem in Iraq with an estimated prevalence of 45/ and mortality rate of 12/  Multi – drug resistant Tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis resistant to both Isoniazid and Rifampicin, is a world problem with an estimated cases in The rate of MDR-TB in Iraq is reported to be 3.4 % of the new TB cases.

 Early detection of MDR- TB provides better treatment outcomes and reduces the transmission of MDR.  Nucleic Acid amplification test (NAAT) like Line Probe Assays have been recently approved for use in low income settings and can be used to screen smear – positive sputum specimens for diagnosis resistance to Rifampicin and Isoniazid in (1-2) days.

The specific objective of this study was to determine the type of MDR –TB and detection the mutation in rpoB, KatG and inhA genes from culture specimens.

 Patients During the study interval (April August 2011), the Institute of Chest and Respiratory diseases in Baghdad received 2866 suspected TB patients with pulmonary and extrapulmoary, 1754(61.2%) male and 1112 (38.7%) females, with age rang from (7 month – 85 years), of which (51) patients as MDR.

Direct examination by ZN and Florescent stain DNA extraction SAMPLE COLLECTION Processing / Decontamination Culture Staining and Biochemical Tests PCR technique and Hybridization with MTBDR plus strips

Genotyping Methods : All genotyping methods were performed at the Emerging Bacterial Pathogens Unit, WHO / IUATLD Supra-National Reference TB Laboratory / San Raffaele Scientific Institute (HSR)- Italy.

Chromogen (MBT/BCIP ) Alkaline Phosphatase Streptavidin Biotin Nitrocellulose strip DNA-probe Biotin-labelled single stranded amplified target Colour reaction

Control of the conjugate - Amplification control - Amplification control MTBC - Control rpoB - rpoB Wild type 1 - rpoB Wild type 2 - rpoB Wild type 3 - rpoB Wild type 4 - rpoB Wild type 5 - rpoB Mut D516V - rpoB Mut H526Y - rpoB Mut H526D - rpoB Mut S531L - Control katG - katG wild type - katG S315T1 (ACC) - katG S315T2 (ACA )

 The most common genetic mutation conferring RIF resistance was S531L of rpoB gene which detected in 33 (82.5%) resistant strains.  Other mutations in this gene were D516Vand H526Y which detected in single strain (2.5%) for each.  Isonaiazid (INH) resistance due to KatG mutation S315T1 was found in 17 (42.5%) strains of (INH) – resistant M. tuberculosis  The second most common site of mutation was in the upstream promoter sequence of inhA, which found in 15 (37.5%)

Results RMP+INH Resistance 51 MDR strains (17) strains INH with mutations in codon of katG (34) strains RIF mutations in rpoB at S531 L region (1) Strain RIF mutation in rpoB at D516V 14 strains with a mutation in inhA + (1) strains with a mutation in KatG and inhA 9 strains with no mutation in katG and inhA 6 strain not detected + 5 strains detected as sensitive to RIF and INH BY MTBDR Plus Strains resistance with no mutation in rpoB +

Rapid Diagnosis of (MDR-TB) using molecular Line probe Assay GeneBand Gene region or mutation MDR strains RIF monoresistant INH monoresistant rpoBWT WT WT WT WT WT WT WT MUT1D516V1 MUT2AH526Y1 MUT2BH526D MUT3S531L 276 KatGWT315 MUT1S315T114 3 MUT2S315T2 inhAWT1-15/-16 WT2-8 MUT1C15T14 MUT2A16G MUT3AT8C MUT3BT8A1

Conclusions Line Probe Assay is an appropriate tool for rapid screening for MDR-TB and has the potential to substantially reduce the turnaround time of drug sensitive test (DST) results. Time for the detection has a potential to reduce the extend of spread of resistant strains

Drug Susceptibility Testing days weeks Solid Media Löwenstein-Jensen Liquid Media BACTEC 460 TB MGIT Molecular based Methods GenoTypeMTBD Hours – 1day